ATE403418T1 - Verfahren zur herstellung von festen dosierformen von amorphem valganciclovir-hydrochlorid - Google Patents

Verfahren zur herstellung von festen dosierformen von amorphem valganciclovir-hydrochlorid

Info

Publication number
ATE403418T1
ATE403418T1 AT05708710T AT05708710T ATE403418T1 AT E403418 T1 ATE403418 T1 AT E403418T1 AT 05708710 T AT05708710 T AT 05708710T AT 05708710 T AT05708710 T AT 05708710T AT E403418 T1 ATE403418 T1 AT E403418T1
Authority
AT
Austria
Prior art keywords
dosage forms
solid dosage
amorphic
producing solid
valganciclovir hydrochloride
Prior art date
Application number
AT05708710T
Other languages
English (en)
Inventor
Romi Singh
Vishnubhotla Nagaprasad
Nidhi Singh
Original Assignee
Ranbaxy Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Lab Ltd filed Critical Ranbaxy Lab Ltd
Application granted granted Critical
Publication of ATE403418T1 publication Critical patent/ATE403418T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AT05708710T 2004-03-10 2005-03-10 Verfahren zur herstellung von festen dosierformen von amorphem valganciclovir-hydrochlorid ATE403418T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN410DE2004 2004-03-10

Publications (1)

Publication Number Publication Date
ATE403418T1 true ATE403418T1 (de) 2008-08-15

Family

ID=34961286

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05708710T ATE403418T1 (de) 2004-03-10 2005-03-10 Verfahren zur herstellung von festen dosierformen von amorphem valganciclovir-hydrochlorid

Country Status (5)

Country Link
US (1) US20070292499A1 (de)
EP (1) EP1725217B1 (de)
AT (1) ATE403418T1 (de)
DE (1) DE602005008721D1 (de)
WO (1) WO2005087198A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008071573A2 (en) * 2006-12-13 2008-06-19 F. Hoffmann-La Roche Ag Powder formulation for valganciclovir
US20100298564A1 (en) * 2009-05-25 2010-11-25 Venu Nalivela Preparation of amorphous valganciclovir hydrochloride
CN104055746B (zh) * 2014-07-12 2017-06-30 河北仁合益康药业有限公司 一种盐酸缬更昔洛韦包衣片剂组合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5292534A (en) * 1992-03-25 1994-03-08 Valentine Enterprises, Inc. Sustained release composition and method utilizing xanthan gum and an active ingredient
US5840891A (en) * 1994-07-28 1998-11-24 Syntex (U.S.A.) Inc. 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3-propanediol derivative
US6395029B1 (en) * 1999-01-19 2002-05-28 The Children's Hospital Of Philadelphia Sustained delivery of polyionic bioactive agents
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
ATE313319T1 (de) * 1999-03-31 2006-01-15 Janssen Pharmaceutica Nv Vorgelatinierte stärke in einer formulierung mit gesteuerter freigabe
US6660303B2 (en) * 1999-12-06 2003-12-09 Edward Mendell & Co. Pharmaceutical superdisintegrant
AR040680A1 (es) * 2002-07-25 2005-04-13 Pharmacia Corp Composicion de tabletas de liberacion sostenida
CN1860120A (zh) * 2003-08-28 2006-11-08 兰贝克赛实验室有限公司 无定形盐酸缬更昔洛韦
US8771735B2 (en) * 2008-11-04 2014-07-08 Jazz Pharmaceuticals, Inc. Immediate release dosage forms of sodium oxybate

Also Published As

Publication number Publication date
US20070292499A1 (en) 2007-12-20
EP1725217A1 (de) 2006-11-29
DE602005008721D1 (de) 2008-09-18
WO2005087198A1 (en) 2005-09-22
EP1725217B1 (de) 2008-08-06

Similar Documents

Publication Publication Date Title
ATE544754T1 (de) Verfahren zur herstellung von ivabradinhydrochlorid
CY1117841T1 (el) Διεργασια για την παρασκευη υδροχλωρικης οξυκωδονης εχουσας λιγοτερο απο 25 ppm 14-yδροξυκωδεϊνονη
ATE444950T1 (de) Verfahren zur herstellung von 1-amino-3,5- dimethyladamantan-hydrochlorid
ATE425136T1 (de) Verfahren zur herstellung substituierter 3-aryl- butyl-aminverbindungen
ATE475655T1 (de) Verfahren zur herstellung von (s)-4- fluormethyldihydrofuran-2-on
DE502005009604D1 (de) Verfahren zur herstellung von ameisensäure
ATE542803T1 (de) Verfahren zur herstellung von dihydrochinazolinen
DE602006018429D1 (de) Verfahren zur herstellung von verschlüssen
ATE537136T1 (de) Neues verfahren zur herstellung von säurechloriden
DE602005017099D1 (de) Verfahren zur Herstellung von amorphem Cefuroximaxetil
ATE539054T1 (de) Verfahren zur herstellung von dihydropyrrolderivaten als zwischenprodukte
ATE544566T1 (de) Verfahren zur herstellung von dünne metallnanodrähte durch biotemplating
MA32943B1 (fr) Piperidine spiro pyrrolidione et piperidinone substituees, leur preparation et leur utilisation therapeutique
CY1112520T1 (el) Βενζυλαμινες, μια διαδικασια για την παραγωγη τους και η χρηση τους ως αντι-φλεγμονωδεις παραγοντες
DE602007001567D1 (de) Verfahren zur Herstellung von Fotomasken-Rohlingen
EA200801893A1 (ru) Производные тетрагидронафталина, способ их получения и их применение в качестве ингибиторов воспаления
ATE489352T1 (de) Verfahren zur herstellung von brenztraubensäure
EA200700807A1 (ru) Новые циклические и ациклические пропеноны для лечения заболеваний цнс
ATE354583T1 (de) Verfahren zur herstellung c-7 substituierter 5- androstene
EA200801573A1 (ru) Способ получения кристаллических форм орлистата
ATE403418T1 (de) Verfahren zur herstellung von festen dosierformen von amorphem valganciclovir-hydrochlorid
ATE549315T1 (de) Verfahren zur herstellung von kristallinem perindopril
ATE466010T1 (de) Verfahren zur herstellung von candesartan
DE602006013688D1 (de) Neues verfahren zur herstellung von thoc
DE602005013007D1 (de) Verfahren zur herstellung von lactonen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties